Edward Feener - Kalvista Pharmaceuticals Chief Scientific Officer
| KALV Stock | USD 8.56 0.19 2.17% |
Executive
Mr. Edward P. Feener Ph.D. is the Chief Scientific Officer of the Company. Edward P. Feener, Ph.D., is a scientific cofounder of KalVista and joined as our Chief Scientific Officer in November 2016. Previously, Dr. Feener was an Associate Professor of Medicine at Harvard Medical School and Senior Investigator in the Section on Vascular Cell Biology at Joslin Diabetes Center from July 1989 to October 2016. He has more than 27 years of research experience in vascular biology and diabetic complications. His laboratory identified novel mechanisms of action for the plasma kallikrein system, which are implicated in diabetic macular edema, vascular injury, and angioedema. since 2016.
| Age | 64 |
| Tenure | 9 years |
| Address | 55 Cambridge Parkway, Cambridge, MA, United States, 02142 |
| Phone | 857 999 0075 |
| Web | https://www.kalvista.com |
Kalvista Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.5394) % which means that it has lost $0.5394 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.9084) %, meaning that it created substantial loss on money invested by shareholders. Kalvista Pharmaceuticals' management efficiency ratios could be used to measure how well Kalvista Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Kalvista Pharmaceuticals' Return On Capital Employed is fairly stable compared to the past year. Return On Equity is likely to climb to 0.17 in 2025, despite the fact that Return On Tangible Assets are likely to grow to (1.03). At this time, Kalvista Pharmaceuticals' Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to climb to about 11.7 M in 2025, despite the fact that Return On Tangible Assets are likely to grow to (1.03).Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| David MD | Immunocore Holdings | 54 | |
| JoAnn Suzich | Immunocore Holdings | N/A | |
| Jennifer Johansson | Larimar Therapeutics | N/A | |
| Andrew Callos | Cytokinetics | 56 | |
| Rocio Hoyos | Kronos Bio | N/A | |
| Colin Love | Replimune Group | 66 | |
| JD Esq | Kura Oncology | 54 | |
| Paul Bullock | Replimune Group | N/A | |
| Marc MD | Edgewise Therapeutics | 68 | |
| Ashish MBA | Dyne Therapeutics | N/A | |
| Steven JD | Cytokinetics | 66 | |
| Anthony Casciano | Viridian Therapeutics | 48 | |
| MPH DO | Kronos Bio | 60 | |
| Matt Cravets | Gossamer Bio | N/A | |
| Marc Damelin | Mersana Therapeutics | N/A | |
| Helen Milton | Viridian Therapeutics | N/A | |
| Jeff Lotz | Cytokinetics | N/A | |
| Pamela Esposito | Replimune Group | 50 | |
| Mary Fenton | Cullinan Oncology LLC | 60 | |
| Steven Cook | Cytokinetics | 65 | |
| Emily Hill | Replimune Group | 45 | |
Management Performance
| Return On Equity | -0.91 | ||||
| Return On Asset | -0.54 |
Kalvista Pharmaceuticals Leadership Team
Elected by the shareholders, the Kalvista Pharmaceuticals' board of directors comprises two types of representatives: Kalvista Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Kalvista. The board's role is to monitor Kalvista Pharmaceuticals' management team and ensure that shareholders' interests are well served. Kalvista Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Kalvista Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jarrod Aldom, Vice Communications | ||
| Nicole Sweeny, Chief Officer | ||
| Ryan Baker, Head Relations | ||
| Benjamin Palleiko, Chief President | ||
| Brian Piekos, Chief Officer | ||
| John McKune, VP Fin | ||
| Thomas MBA, CEO Director | ||
| Michael PharmD, Senior Development | ||
| Christopher Yea, Chief Development Officer | ||
| MD MBA, Chief Officer | ||
| Stephen Donnelly, Director Secretary | ||
| Rachel Morten, Senior QA | ||
| Edward Feener, Chief Scientific Officer | ||
| Brian JD, General Counsel |
Kalvista Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Kalvista Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.91 | ||||
| Return On Asset | -0.54 | ||||
| Current Valuation | 280.61 M | ||||
| Shares Outstanding | 49.42 M | ||||
| Shares Owned By Insiders | 1.35 % | ||||
| Shares Owned By Institutions | 98.65 % | ||||
| Number Of Shares Shorted | 7.45 M | ||||
| Price To Earning | (2.82) X | ||||
| Price To Book | 3.06 X | ||||
| Price To Sales | 107.42 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Kalvista Stock Analysis
When running Kalvista Pharmaceuticals' price analysis, check to measure Kalvista Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kalvista Pharmaceuticals is operating at the current time. Most of Kalvista Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Kalvista Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kalvista Pharmaceuticals' price. Additionally, you may evaluate how the addition of Kalvista Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.